IMAC Holdings Forms Ignite Proteomics to Enhance Personalized Therapy for Cancer Patients

January 28, 2025

DENVER, Colo., Jan 28, 2025 (247marketnews.com)- IMAC Holdings (NASDAQ: BACK) has taken what it promises to be a bold step in revolutionizing cancer treatment with the launch of Ignite Proteomics LLC, a new subsidiary focused on enhancing personalized therapy for cancer patients through protein-level insights. This move addresses a critical oncology need: more accuracy in quickly matching patients with the most effective treatments.

IMAC Holdings (NASDAQ:BACK) has taken what it promises to be a bold step in revolutionizing cancer treatment with the launch of Ignite Proteomics LLC, a new subsidiary focused on enhancing personalized therapy for cancer patients through protein-level insights. This move addresses a critical oncology need: more accuracy in quickly matching patients with the most effective treatments.

While genomics-based testing has become a cornerstone of personalized medicine, it often falls short of providing the full picture. Genomic tests identify the genetic potential of cancer, but fail to offer real-time insights into tumor behavior and treatment responses. Proteins, on the other hand, are the functional drivers of cancer cell activity and the direct targets of many modern cancer therapies, including antibody-drug conjugates (ADCs) and immunotherapies. By focusing on protein-level data, Ignite is poised to disrupt the multi-billion-dollar genomic testing market, offering a more comprehensive and immediate method to guide treatment decisions.

Ignite’s multi-protein test provides a richer, more nuanced view of a tumor’s activity and response to therapies. Unlike traditional genomic tests, which often miss crucial signals, Ignite’s platform measures a wide range of proteins in a single sample, offering a unique and dynamic snapshot of a cancer’s behavior. This allows for more precise and effective treatment selections, especially when dealing with the increasingly complex therapies like ADCs and immunotherapies.

IMAC’s CEO Faith Zaslavsky emphasized the importance of protein insights, stating, “Gene tests alone don’t tell us enough about how to pick the right therapies. Proteins are what guide a cancer’s behavior and drug response.” By leveraging these real-time protein signals, Ignite aims to reduce the trial-and-error approach that often delays effective treatment, ultimately improving patient outcomes.

Looking ahead, Ignite Proteomics is expanding its reach by collaborating with leading cancer centers to further validate its approach and integrate its test into routine care. As ADCs and immunotherapies continue to evolve, the demand for precise insights into tumor behavior will only grow, and Ignite’s protein-level approach is well-positioned to meet this need. With a focus on filling the gaps left by genomic testing, Ignite is on track to set a new standard in personalized oncology, helping physicians make better-informed decisions and guiding patients to the most effective treatments faster.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BACK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.